WO2002009726A1 - Procedes de traitement des affections asociees a la resistance a l'insuline avec l'aicar, (5-amino-4-imidazole carboxamide riboside) et de composes apparentes - Google Patents

Procedes de traitement des affections asociees a la resistance a l'insuline avec l'aicar, (5-amino-4-imidazole carboxamide riboside) et de composes apparentes Download PDF

Info

Publication number
WO2002009726A1
WO2002009726A1 PCT/US2001/024194 US0124194W WO0209726A1 WO 2002009726 A1 WO2002009726 A1 WO 2002009726A1 US 0124194 W US0124194 W US 0124194W WO 0209726 A1 WO0209726 A1 WO 0209726A1
Authority
WO
WIPO (PCT)
Prior art keywords
aicar
insulin resistance
disease
ampk
glucose
Prior art date
Application number
PCT/US2001/024194
Other languages
English (en)
Other versions
WO2002009726A9 (fr
Inventor
Neil Ruderman
Edward W. Kraegen
Yasuo Ido
Original Assignee
Trustees Of Boston University
Garvan Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/040607 external-priority patent/WO2001010449A1/fr
Priority claimed from PCT/US2001/018467 external-priority patent/WO2001093873A1/fr
Application filed by Trustees Of Boston University, Garvan Institute filed Critical Trustees Of Boston University
Priority to US10/343,399 priority Critical patent/US20030212014A1/en
Priority to AU2001283083A priority patent/AU2001283083A1/en
Publication of WO2002009726A1 publication Critical patent/WO2002009726A1/fr
Publication of WO2002009726A9 publication Critical patent/WO2002009726A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Abstract

L'utilisation à long terme d'AICAR (5-amino-4-imidazole carboxamide riboside) pour susciter des changements métaboliques et biologiques durables chez un mammifère permet de vaincre la résistance à l'insuline (augmente par exemple la sensiblement à l'insuline) et apporte des améliorations concernant des maladies et des pathologies telles que le diabète, l'hypertension, l'athérosclérose, le syndrome des ovaires polykystiques et les affections biliaires. L'utilisation à long terme d'AICAR, notamment son administration intermittente (par exemple trois jours par semaine) semble avoir quelques effets positifs, une incidence sur la quantité de nourriture consommée par un sujet, et entraîner une réduction de l'accumulation des matières grasses et une augmentation de la masse musculaire. Par conséquent, l'administration d'AICAR influe positivement sur la diminution de l'obésité. AICAR peut également s'avérer utile pour la prévention ou le traitement de maladies vasculaires associées à l'hyperglycémie, à une concentration plasmique élevée d'acides gras libres (AGL) et de triglycéride, ou à la résistance à l'insuline, du fait que cet agent active l'oxydation des acides gras. Des essais réalisés sur des animaux montrent qu'un traitement intermittent prolongé avec AICAR n'a produit aucun effet toxique notable. AICAR et les composés qui lui sont associés sont des activateurs de la protéine kinase activée par AMP (AMPK) et peuvent, en outre, faire baisser efficacement la concentration de malonyle CoA chez l'animal.
PCT/US2001/024194 2000-07-31 2001-07-31 Procedes de traitement des affections asociees a la resistance a l'insuline avec l'aicar, (5-amino-4-imidazole carboxamide riboside) et de composes apparentes WO2002009726A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/343,399 US20030212014A1 (en) 2000-08-09 2001-07-31 Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
AU2001283083A AU2001283083A1 (en) 2000-07-31 2001-07-31 Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22213100P 2000-07-31 2000-07-31
US60/222,131 2000-07-31
USPCT/US00/40607 2000-08-09
PCT/US2000/040607 WO2001010449A1 (fr) 1999-08-09 2000-08-09 Technique permettant de maintenir l'integrite vasculaire a l'aide de l'aicar (5-amino-4-imidazole riboside) et de composes associes
USPCT/US01/18467 2001-06-06
PCT/US2001/018467 WO2001093873A1 (fr) 2000-06-06 2001-06-06 Utilisation de aicar et de composes associes

Publications (2)

Publication Number Publication Date
WO2002009726A1 true WO2002009726A1 (fr) 2002-02-07
WO2002009726A9 WO2002009726A9 (fr) 2003-09-12

Family

ID=27359029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024194 WO2002009726A1 (fr) 2000-07-31 2001-07-31 Procedes de traitement des affections asociees a la resistance a l'insuline avec l'aicar, (5-amino-4-imidazole carboxamide riboside) et de composes apparentes

Country Status (1)

Country Link
WO (1) WO2002009726A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083380A2 (fr) * 2003-03-13 2004-09-30 Duke University Procedes et compositions pour moduler une synthese et une decomposition de glycogene
WO2005089773A1 (fr) * 2004-03-18 2005-09-29 Fasgen, Llc Regulation du comportement alimentaire par modification du bilan energetique neuronal
WO2008006432A1 (fr) 2006-07-13 2008-01-17 Merck Patent Gmbh Utilisation de dérivés d'imidazole activateurs d'ampk, procédé de préparation de ces composés, et compositions pharmaceutiques pourvues de ceux-ci
US7560435B2 (en) 2002-03-21 2009-07-14 Advanced In Vitro Cell Technologies, S. A. Therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
US20110112047A1 (en) * 2006-12-29 2011-05-12 Evans Ronald M Methods for enhancing muscle performance and tone
WO2014036528A2 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
WO2020050935A2 (fr) 2018-08-06 2020-03-12 Skylark Bioscience Llc Composés activant la protéine kinase activée par l'amp et leurs utilisations
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560435B2 (en) 2002-03-21 2009-07-14 Advanced In Vitro Cell Technologies, S. A. Therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
WO2004083380A2 (fr) * 2003-03-13 2004-09-30 Duke University Procedes et compositions pour moduler une synthese et une decomposition de glycogene
WO2004083380A3 (fr) * 2003-03-13 2005-04-07 Univ Duke Procedes et compositions pour moduler une synthese et une decomposition de glycogene
WO2005089773A1 (fr) * 2004-03-18 2005-09-29 Fasgen, Llc Regulation du comportement alimentaire par modification du bilan energetique neuronal
AU2005222707B2 (en) * 2004-03-18 2010-06-17 Fasgen, Llc Control of feeding behavior by changing neuronal energy balance
WO2008006432A1 (fr) 2006-07-13 2008-01-17 Merck Patent Gmbh Utilisation de dérivés d'imidazole activateurs d'ampk, procédé de préparation de ces composés, et compositions pharmaceutiques pourvues de ceux-ci
US20110112047A1 (en) * 2006-12-29 2011-05-12 Evans Ronald M Methods for enhancing muscle performance and tone
US9192601B2 (en) * 2006-12-29 2015-11-24 Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
WO2014036528A2 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
WO2020050935A2 (fr) 2018-08-06 2020-03-12 Skylark Bioscience Llc Composés activant la protéine kinase activée par l'amp et leurs utilisations
US11834469B2 (en) 2018-08-06 2023-12-05 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Also Published As

Publication number Publication date
WO2002009726A9 (fr) 2003-09-12

Similar Documents

Publication Publication Date Title
Jiang et al. Diabetic‑induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus
Jankauskas et al. Heart failure in diabetes
Witters The blooming of the French lilac
Szkudelska et al. Resveratrol, obesity and diabetes
Gratia et al. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress
Kim et al. Prevention of fat-induced insulin resistance by salicylate
Yan et al. FOXO1 contributes to diabetic cardiomyopathy via inducing imbalanced oxidative metabolism in type 1 diabetes
Barrachina et al. Role of nitric oxide in gastrointestinal inflammatory and ulcerative diseases: perspective for drugs development
Neschen et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA: glycerol-sn-3-phosphate acyltransferase 1 knockout mice
Bevilacqua et al. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects
Stanley et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions
Liepinsh et al. Protective effects of mildronate in an experimental model of type 2 diabetes in Goto‐Kakizaki rats
Saha et al. Cytosolic citrate and malonyl-CoA regulation in rat muscle in vivo
Tabernero et al. Activation of the peroxisome proliferator-activated receptor α protects against myocardial ischaemic injury and improves endothelial vasodilatation
Kusmic et al. Improved myocardial perfusion in chronic diabetic mice by the up‐regulation of pLKB1 and AMPK signaling
Yang et al. Insulin stimulates Akt translocation to mitochondria: implications on dysregulation of mitochondrial oxidative phosphorylation in diabetic myocardium
Shamoon et al. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus.
Commerford et al. Diets enriched in sucrose or fat increase gluconeogenesis and G-6-Pase but not basal glucose production in rats
Pil Hwang et al. 3‐Caffeoyl, 4‐dihydrocaffeoylquinic acid from S alicornia herbacea attenuates high glucose‐induced hepatic lipogenesis in human H ep G 2 cells through activation of the liver kinase B 1 and silent information regulator T 1/AMPK‐dependent pathway
Chong et al. Drugs that affect cardiac metabolism: focus on perhexiline
WO2002009726A1 (fr) Procedes de traitement des affections asociees a la resistance a l'insuline avec l'aicar, (5-amino-4-imidazole carboxamide riboside) et de composes apparentes
Bae et al. Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate–activated protein kinase–p70 ribosomal S6 kinase‐1 pathway
Grossini et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig
US20030212014A1 (en) Methods fo treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds
Yaspelkis III et al. Exercise reverses high-fat diet-induced impairments on compartmentalization and activation of components of the insulin-signaling cascade in skeletal muscle

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10343399

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/34-34/34, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP